華康生物醫學：2021年報.pdf

1、ANNUAL REPORT年報2021(incorporated in the Cayman Islands with limited liability)(於開曼群島註冊成立之有限公司)Stock Code 股份代號:8622Huakang Biomedical Holdings Company Limited華康生物醫學控股有限公 司Huakang Biomedical Holdings Company Limited華康生物醫學控股有限公 司Huakang Biomedical Holdings Company Limited 華康生物醫學控股有限公司Annual Report 2021

2、 年報CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED(THE“STOCK EXCHANGE”)香港聯合交易所有限公司（聯交所）GEM之特色GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange

3、.Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.Given that the companies listed on GEM are generally small and mid-sized companies,there is a risk that securities traded on GE

4、M may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for t

5、he contents of this report(“Report”),make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of the Report.This Report,for which the directors(the“Directors

6、”)of Huakang Biomedical Holdings Company Limited(the“Company”,and together with its subsidiaries,the“Group”,“we”or“our”)collectively and individually accept full responsibility,includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange(th